FRANCE: En Carta Diagnostics, a deeptech start-up developing rapid Point-of-Care (POC) molecular diagnostics kits, has announced €1.5M ($1.63M) in pre-seed funding. This investment will enable En Carta to make a substantial leap forward in achieving preclinical data on a prototype diagnostic kit for its flagship indication, the debilitating Lyme disease, while ensuring its ability to scale industrially.